Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Sarepta's Launch Of Exondys 51 Likely Slower Than Expected As Payers Deny Or Restrict Coverage

Sarepta's Launch Of Exondys 51 Likely Slower Than Expected As Payers Deny Or Restrict Coverage

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares nearly doubled back in September after the FDA granted accelerated approval for the company’s first drug, EXONDYS 51. However, after conducting a round of due diligence by talking to private payers and other experts, Jefferies analyst Gena Wang believes EXONDYS 51 uptake may be delayed.


Wang spoke to four private payers, three Medicaid experts and two Duchenne Muscular Dystrophy (DMD) experts. In addition, she reviewed published medical policies from 21 other private payers.

According to Jefferies, 3/5 national and 8/15 regional managed care organizations have either denied or limited their coverage of EXONDYS 51.

“There appears to be no legal consequence, according to KOLs, for payers (Medicaid and private) to restrict/deny coverage, citing clinical benefits as #1 criteria for coverage decisions and FDA approval status as secondary,” Wang explained.

She isn’t surprised by the push-back and expects the road ahead for EXONDYS 51 to be an uphill climb.


“Our analysis suggests likely slow uptake of Exondys 51 due to additional time required for genetic tests, uncertainty of clinical benefits, and exhaustive payer oversight; decisions to continue would likely depend on close monitoring of clinical benefits, safety and pt interest,” Wang noted.

Jefferies maintains a Hold rating on Sarepta’s stock and a $46 price target.

At last check, shares of Sarepta were down 5.88 percent at $29.95.

Latest Ratings for SRPT

May 2019MaintainsBuy
May 2019MaintainsOverweight
May 2019MaintainsOutperform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Exondys 51Analyst Color Biotech News FDA Analyst Ratings Movers General Best of Benzinga


Related Articles (SRPT)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Is This The End Of The Rally In Financials?

Bank Of America Refuses To Retreat For Now